This was the stock's third consecutive day of losses.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.

Shares of NASDAQ:INO opened at $1.98 on Friday. The company has a 50-day moving average price of $3.42 and a two-hundred day moving average price of $6.10. Inovio Pharmaceuticals has a twelve ...

Shares of NASDAQ INO opened at $1.98 on Friday. The company has a market capitalization of $51.68 million, a PE ratio of -0.95 and a beta of 0.84. Inovio Pharmaceuticals has a twelve month low of ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.

Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour. Regeneron’s drug ...

This was the stock's second consecutive day of losses.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.